Feedback / Questions
pro-doxorubicin (AVA6000) - Avacta
https://www.businesswire.com/news/home/20230405005422/en/Avacta-Announces-First-Patient-Dosed-in-Fifth-Cohort-of-AVA6000-Phase-Ia-Dose-Escalation-Study
Apr 5, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next